Welcome to our dedicated page for CALITHERA BIOSCIENCES news (Ticker: CALA), a resource for investors and traders seeking the latest updates and insights on CALITHERA BIOSCIENCES stock.
Calithera Biosciences Inc. (CALA) is a pioneering biopharmaceutical company dedicated to the discovery and development of first-in-class small molecule drugs aimed at slowing tumor growth. Their approach focuses on controlling key metabolic pathways in both tumor and immune cells, targeting the distinct metabolic requirements of these cells to impede cancer proliferation.
Calithera leverages the promising fields of tumor metabolism and tumor immunology to create new, innovative cancer therapies. Recent clinical successes highlight the potential of their investigational medicines to slow abnormal cell growth and offer fundamentally new treatment options for cancer patients.
Currently, Calithera's lead candidate is in Phase 2 trials for patients with renal cell carcinoma and triple negative breast cancer. These trials are crucial given the urgent need for new treatments in these solid tumors.
Calithera also engages in strategic partnerships to bolster its research and development efforts. Their onco-metabolism approach aims to bring a fresh perspective to cancer treatment by exploiting the unique metabolic needs of cancer cells versus cancer-fighting immune cells.
For more information, latest updates, and significant news regarding Calithera Biosciences Inc., visit their official webpage or contact them directly.
Calithera Biosciences announced promising interim results from its Phase 1b trial of CB-280, an arginase inhibitor for cystic fibrosis. Data showed the drug was well-tolerated with a positive safety profile across all dose levels. Notable trends included increased fractional exhaled nitric oxide (FeNO) and decreased sweat chloride. Early observations suggested improved forced expiratory volume in one second (FEV1), a key safety endpoint. The study enlisted 24 subjects, primarily on CFTR modulators, and aims to provide new therapeutic options for cystic fibrosis patients.
Calithera Biosciences, Inc. (CALA) announced data from its Phase 1b trial of CB-280, an investigational arginase inhibitor for cystic fibrosis, to be presented at the North American Cystic Fibrosis Conference virtual event from November 2-5, 2021.
CB-280 aims to be a first-in-class oral therapy for all CF patients. The poster presentation details include a randomized, double-blind, placebo-controlled trial focusing on the drug's potential benefits. The clinical trial's outcome could significantly affect Calithera's future and stock performance.
Calithera Biosciences has entered into an agreement with Takeda to acquire two promising clinical-stage compounds: sapanisertib and mivavotinib. The $10 million upfront cash payment and $35 million in preferred stock aim to enhance Calithera's precision oncology pipeline, focusing on biomarker-defined cancer patient populations. Sapanisertib targets NRF2 mutations in squamous non-small cell lung cancer, while mivavotinib serves as a potential best-in-class SYK inhibitor for non-Hodgkin's lymphoma. Phase 2 trials for both compounds are set to initiate in 2022.
Calithera Biosciences announced the KEAPSAKE Phase 2 trial evaluating telaglenastat in combination with chemotherapy for patients with non-small cell lung cancer (NSCLC) and KEAP1/NRF2 mutations. The trial will enroll around 120 patients and aims to demonstrate improved progression-free survival. The trial's interim data will be shared in the fourth quarter of 2021 at the IASLC 2021 World Conference on Lung Cancer. This investigational drug is designed to inhibit glutamine consumption in tumors, showing promise for NSCLC treatment.
Calithera Biosciences, a clinical-stage biotechnology company, announced its participation in two virtual healthcare investor conferences. On September 8, 2021, the company will host virtual meetings at Citi's 16th Annual BioPharma Virtual Conference. Additionally, CEO Susan M. Molineaux will speak at the 2021 Virtual Wells Fargo Healthcare Conference on September 9, 2021, at 2:40 p.m. ET. A live audio webcast of the Wells Fargo presentation will be available on the company's website, with a replay accessible for 30 days thereafter.
Calithera Biosciences (CALA) reported financial results for Q2 2021, with cash, cash equivalents, and investments totaling $92.2 million. The company signed a worldwide license agreement with Antengene for CB-708, receiving an upfront payment and potential milestones up to $252 million. Revenue for the quarter was $3.0 million from the Antengene license. R&D expenses decreased to $12.8 million from the previous year. The net loss was $14.3 million. Calithera continues its clinical trials for telaglenastat and CB-280 and anticipates key data releases in Q4 2021.
Calithera Biosciences (CALA) will announce its Q2 2021 financial results on August 5, 2021. A conference call is scheduled for 2:00 p.m. PT to cover financial results and recent corporate developments. The press release will be available on their website. Calithera is focused on developing small molecule drugs targeting cancer and other serious diseases, aiming to enhance treatment options through innovative therapies. The company's commitment to scientific rigor is reflected in its ongoing clinical trials.
Calithera Biosciences (Nasdaq: CALA) presented final results from the Phase 2 CANTATA study of its glutaminase inhibitor telaglenastat (CB-839) at the ASCO 2021 Annual Meeting. The study evaluated telaglenastat combined with cabozantinib in advanced renal cell carcinoma (RCC) patients. Results indicated no improvement in progression-free survival (PFS), with a median PFS of 9.2 months for the combination group compared to 9.3 months for the placebo group. Subgroup analysis showed a numerically longer PFS of 11.1 months for those with prior immunotherapy. The findings contribute to understanding RCC treatment.
Calithera Biosciences, a clinical-stage biotechnology company focused on cancer treatments, announced that its founder and CEO, Susan Molineaux, will present at the Jefferies 2021 Virtual Healthcare Conference on June 4, 2021, at 9:00 am ET. Investors can access a live audio webcast of the presentation on Calithera's website, with an archived replay available for 30 days. The company is developing innovative therapies targeting cellular metabolic pathways to enhance cancer treatment options. Forward-looking statements regarding product candidates are subject to risks and uncertainties.
Calithera Biosciences (CALA) has entered into an exclusive global licensing agreement with Antengene for the development of CB-708, a small molecule inhibitor of CD73. This partnership is seen as a significant milestone, validating Calithera's drug discovery capabilities. The agreement includes an upfront payment and potential milestones totalizing up to $255 million. CB-708 demonstrated promise in preclinical studies, showing potential as a best-in-class therapy for cancer treatment. Calithera plans to focus on advancing other clinical programs while Antengene handles the clinical development of CB-708.
FAQ
What is the market cap of CALITHERA BIOSCIENCES (CALA)?
What does Calithera Biosciences Inc. specialize in?
What is the primary focus of Calithera's research?
What are Calithera's lead candidates currently being tested for?
How does Calithera's onco-metabolism approach work?
What recent achievements has Calithera accomplished?
Who can I contact for more information about Calithera?
Where can I find the latest updates on Calithera?
What kind of partnerships does Calithera engage in?
Why is Calithera's research important?
What makes Calithera's therapy approach unique?
